Lex Fridman PodcastFrancis Collins: National Institutes of Health (NIH) | Lex Fridman Podcast #238
CHAPTERS
- 0:00 – 1:45
Framing the conversation: trust in science during a divisive pandemic
Lex sets the tone: tackle controversial COVID-era topics with empathy, humility, and a goal of rebuilding trust in science. Collins agrees to the mission and the discussion begins with origins and accountability.
- •Science as hope vs. science as a source of division
- •Commitment to hard questions with empathy
- •Trust-building as a central theme for the episode
- 1:45 – 4:19
COVID origins: lab-leak plausibility, evidence gaps, and politics vs. science
Collins says a lab leak can’t be ruled out but considers it unlikely, emphasizing the missing transparency and records needed to investigate. He argues the origins question is scientific in nature, but politically charged—especially given US–China tensions and limited collaboration.
- •Lab leak not excluded, but judged unlikely by Collins
- •Natural spillover pathway (bat → intermediate host → humans) as most likely
- •Why origins investigations can take years (SARS, MERS examples)
- •Scientific question with political implications; limited access to Chinese data
- 4:19 – 16:35
Gain-of-function clarified: definitions, oversight, and the Wuhan grant controversy
Collins explains that “gain-of-function” is broadly used in biology but has a narrow meaning in high-risk pathogen oversight (EPPP). He details the stringent review framework, argues most proposals are rejected, and insists the Wuhan bat-virus work did not meet the EPPP threshold or create SARS‑CoV‑2.
- •Distinguishing everyday gain-of-function from EPPP oversight category
- •EPPP applies to known human pathogens with increased transmissibility/virulence risk
- •Only a few high-risk approvals in recent years (influenza)
- •EcoHealth/Wuhan subaward: oversight compliance and reporting failure issue
- •Why studied bat viruses weren’t close enough to be SARS‑CoV‑2’s source (genome similarity argument)
- 16:35 – 20:59
Risk calculus and the future: accidents, biosecurity, and bioterror fears
Lex presses the long-term existential risk of engineered pathogens; Collins agrees risk exists and highlights that federal funding is the area with the most control. They discuss international enforcement gaps, detection efforts (e.g., DNA ordering), and the reality that accidents and incompetence are also major concerns.
- •Benefits vs. risks of high-consequence pathogen research
- •Federal oversight vs. unregulated or malicious actors outside institutions
- •International governance and enforcement are weak (parallels to germline editing)
- •Incompetence/accident risk (SARS lab leaks; biosecurity levels BSL2/3/4)
- •Some monitoring exists (e.g., suspicious oligo orders), but needs strengthening
- 20:59 – 31:01
Anthony Fauci under fire: leadership, truth-telling, and public trust
Collins strongly rejects calls to fire Fauci, framing attacks as politically motivated and detached from truth. Lex argues leaders also bear responsibility for trust and unity; Collins counters that truth-telling and updating guidance with changing evidence are essential even if weaponized by critics.
- •Collins’ defense of Fauci as dedicated public servant
- •Political targeting and the dangers of rewarding disinformation campaigns
- •Why guidance changes aren’t “flip-flops” (data and variants change)
- •Debate on whether humility/contrition could rebuild trust
- •Communicating uncertainty vs. making actionable public recommendations
- 31:01 – 37:20
Vaccine hesitancy and the ‘loss of the anchor of truth’
Collins empathizes with hesitant people, focusing on listening and respectful dialogue about speed, safety, and unknown long-term effects. He warns of a broader societal crisis: truth losing its primacy amid misinformation, polarization, and social-media dynamics; Lex proposes humility and love as effective communication strategies.
- •Common hesitancy drivers: speed, corner-cutting fears, long-term uncertainty
- •Importance of listening without condescension
- •Condemnation of deliberate misinformation as life-threatening
- •Collins’ concern: erosion of shared truth as a civic foundation
- •Lex’s prescription: humility, kindness, better science communication
- 37:20 – 40:28
Joe Rogan, ivermectin, and how to handle ‘insufficient evidence’
Lex asks why Rogan and ivermectin discussions draw intense backlash when NIH says evidence is insufficient. Collins distinguishes ivermectin uncertainty from what he sees as more serious vaccine skepticism, describes harms from misuse, and notes ongoing trials (ACTIV‑6) aimed at settling the question rigorously.
- •NIH stance: insufficient evidence; need well-powered trials
- •Critique of public vaccine negativity during high mortality
- •Harms from inappropriate dosing (livestock formulations, overdoses)
- •ACTIV‑6 trial status and timeline to determine efficacy
- •Skepticism is valid if it leads to engagement with data
- 40:28 – 44:24
Why vaccinate the young and healthy: non-zero risk and community impact
Lex articulates skepticism about vaccination for low-risk groups and children; Collins responds with data-informed arguments and vivid examples of severe disease in healthy individuals. He emphasizes that risk is reduced but not eliminated for younger populations and that broad vaccination reduces transmission and future variant emergence.
- •Healthy, fit people can still face severe outcomes (ICU demographics)
- •Pediatric risk exists (not zero), including deaths
- •Vaccination is framed as safe/effective risk reduction for everyone
- •Population-level benefits: fewer infections, fewer mutations/variants
- 44:24 – 49:06
Variants and endgame strategy: boosters, masks, and global vaccine equity
Collins describes Delta’s dominance and the persistent threat of immune-escape variants. He outlines a multi-part strategy—vaccinating the hesitant, vaccinating children, boosting, and masking indoors—while stressing that global under-vaccination is a variant factory that endangers everyone.
- •Delta’s rapid takeover and ongoing evolution (e.g., Delta sublineages)
- •Main fear: variant sufficiently different to evade vaccines
- •mRNA platform adaptability vs. the cost of delays in redesigning vaccines
- •Domestic strategy: vaccinate, boost, masks/social distancing while needed
- •Global imperative: accelerate vaccine access in low/middle-income countries
- 49:06 – 53:06
Rapid at-home testing and RADx: fixing early failures and scaling solutions
Lex argues cheap daily home testing could have reduced division and empowered individual choice; Collins agrees and details NIH’s role in RADx, community trials, and manufacturing scale-up. They discuss the early testing missteps, antigen test tradeoffs, and the goal of hundreds of millions of tests per month.
- •Early reliance on slow lab PCR pipelines was the wrong model
- •Home antigen testing: imperfect but highly actionable and scalable
- •NIH’s RADx program as a ‘venture capital/shark tank’ accelerator
- •Community-wide testing trials measured via wastewater surveillance
- •Scaling ambitions: hundreds of millions of tests/month
- 53:06 – 58:42
Animal research ethics: oversight, chimpanzee research ban, and moral tradeoffs
Prompted by a viral ‘puppies’ claim, they broaden into the ethics of animal research and institutional oversight. Collins explains the decision to end invasive chimp research, defends tightly reviewed animal studies when essential, and argues that banning all animal research can also be unethical due to lost medical progress.
- •Clarification: disputed NIH funding attribution in the ‘puppies’ story
- •Ending NIH-supported invasive chimp research (2015) after NAS review
- •Oversight mechanisms to justify animal research and minimize suffering
- •Cases where animals are the only viable disease model (e.g., parasites)
- •Ethical comparison to broader animal harms outside research (factory farming)
- 58:42 – 1:02:38
Stepping down from NIH: achievements, leadership philosophy, and exhaustion
Collins reflects on 12 years as NIH Director and why he’s stepping down after serving under three presidents—arguing organizations benefit from new vision. He highlights scientific leaps during his tenure (gene editing, single-cell biology, BRAIN) and the extraordinary pace and rigor of COVID vaccine development.
- •Why transition now: unprecedented tenure; timing for confirmation process
- •Pride points: CRISPR therapies, single-cell advances, BRAIN Initiative
- •COVID vaccines as a culmination of decades of basic science
- •Convening power: catalyzing cross-disciplinary ‘ready-to-breakthrough’ areas
- •Personal cost: 100-hour weeks; desire to find the next calling
- 1:02:38 – 1:12:09
Obama, science leadership, and public–private partnerships (AMP → ACTIV)
Collins shares behind-the-scenes experiences with Barack Obama’s curiosity and questioning, including initiatives like All of Us. He then details building the Accelerating Medicines Partnership (open-access, shared cost), which later enabled the rapid creation of ACTIV to standardize and accelerate COVID trials and therapeutics.
- •Obama’s scientific curiosity and ability to ask the right questions
- •All of Us program: large-scale cohort linking genomes, records, research access
- •AMP: breaking academia–industry stereotypes; open science requirement
- •Expansion of AMP into multiple disease areas and bespoke gene therapy
- •ACTIV built in weeks; master protocols and fast therapeutic/vaccine trials
- 1:12:09 – 1:15:19
Genome as ‘instruction book’: awe, humility, and medicine’s next decades
Turning reflective, Collins describes the Human Genome Project as humanity’s first real glimpse of its biological ‘instruction book.’ He emphasizes how it transformed science and is still transforming medicine, while noting we remain early learners interpreting a three-billion-letter text.
- •Genome as history, parts list, and medical textbook
- •Milestones: 2000 draft announcement; 2001 analysis publication
- •Transformative impact on biomedical research methods
- •Long runway ahead: interpreting regulation and meaning over generations
- 1:15:19 – 1:26:53
Faith, mortality, and meaning: Christianity alongside science
Collins recounts his journey from atheism to Christianity, arguing science and faith address different kinds of questions and can be complementary. He reflects on friendships across worldview divides (Hitchens), his lack of fear of death, and concludes with a faith-based account of life’s meaning centered on love, service, and the Sermon on the Mount.
- •Conversion story: limits of science on meaning, death, and God
- •Compatibility of science and faith; vaccines as science and ‘answer to prayer’
- •Hitchens friendship: intellectual challenge, mutual respect, end-of-life support
- •Mortality at 71: purpose-driven remaining time; no obsession with ‘legacy’
- •Meaning of life: love, altruism, moral striving with forgiveness
